Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.

Date publication

janvier 2022

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr COUDERT Bruno

Tous les auteurs :
Squara PA, Luu VP, Pérol D, Coudert B, Machuron V, Bachot C, Samelson L, Florentin V, Pinguet JM, Ben Hadj Yahia B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35439247

Résumé

This article describes the Personalized Reimbursement Model (PRM) program methodology, limitations, achievement and perspectives in using real-world data of cancer drugs use to improve and personalize drug pricing and reimbursement in France.

Mots clés

Antineoplastic Agents, therapeutic use, Breast Neoplasms, drug therapy, Carcinoma, Non-Small-Cell Lung, drug therapy, Drug Costs, Female, France, Humans, Lung Neoplasms, drug therapy, Retrospective Studies, Trastuzumab, therapeutic use

Référence

PLoS One. 2022 ;17(4):e0267242